Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mar

Today In Oncology

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Partial Gland Removal May Be an Option for Many Men With Prostate Cancer

How the Cancer Moonshot Is Making a Difference for Patients Here and Across the World

Greater Plant Based Oil Lower Butter Intake Could Improve Risk of Cancer Related Mortality

Breast Cancer Mortality Rates May Have Stopped Declining

SGLT2 Inhibitors Could Help Protect Against Heart Failure in Patients With Cancer